Acer Therapeutics jumps on starting trial for inherited disorder drug

Acer Therapeutics

27/06/2022 18:53

** Shares of Acer Therapeutics Inc  ACER.O  rise 17% to
$1.43 in afternoon trade - on course for the biggest one-day pct
jump in more than a year
    ** ACER says it started patient screening in its late-stage
clinical trial of Edsivo, its experimental treatment for
patients with a severe form of an inherited disorder that
affects connective tissues such as skin and blood vessel walls
 urn:newsml:reuters.com:*:nGNX1Qxcrg
    ** Company plans to enroll about 150 U.S. patients with
vascular Ehlers-Danlos Syndrome (VEDS) in the trial
   ** VEDS, for which currently there are no FDA-approved
therapies, could cause walls of blood vessels, intestines or
uterus to rupture
    ** The U.S. FDA had declined to approve Edsivo for the
connective tissue disorder in 2019, asking for one more trial of
the drug
    ** Stock down 37% YTD
    

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))